The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man.
Anti-inflammatory properties may contribute to the pharmacological effects of angiotensin II receptor blockers (ARBs), a leading therapeutic class in the management of hypertension and related cardiovascular and renal diseases. That possibility, supported by consistent evidence from in-vitro and animal studies showing pro-inflammatory properties of angiotensin II, has been evaluated clinically by measuring the effect of ARBs on C-reactive protein and other circulating indices of inflammation (e-selectin, adhesion molecules, interleukin-6, tissue necrosis factor-alpha, monocyte chemoattractant protein-1) of potential clinical relevance, a body of evidence that this paper aims to review.
Dipartimento Cardio Toracico e Vascolare, Università di Pisa, Italy.
Alessandra
A
Del Fiorentino
Silvana
S
Cianchetti
Alessandro
A
Celi
Giulia
G
Dell'Omo
Roberto
R
Pedrinelli
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D015815:Cell Adhesion Molecules / Q000097:blood; D018925:Chemokines / Q000097:blood; D016207:Cytokines / Q000097:blood; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000188:drug therapy*; D018836:Inflammation Mediators / Q000097:blood*
D047228:Angiotensin II Type 1 Receptor Blockers; D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D015815:Cell Adhesion Molecules; D018925:Chemokines; D016207:Cytokines; D018836:Inflammation Mediators; D002097:C-Reactive Protein